EE196 Healthcare Resource Use Among Patients Treated with Lurasidone or Cariprazine for Depressive Episodes Associated with Bipolar I Disorder

Bipolar I disorder (BPD-1) is a chronic mood characterized by manic and depressive episodes that produces substantial financial burden in the US. This retrospective chart review study compared healthcare resource utilization (HRU) among patients with associated BPD-1 treated lurasidone or cariprazine, two atypical antipsychotics approved for treatment of bipolar depression. Data on adult prescribed cariprazine after June 2019 were collected from patient medical charts clinicians US 2021. HRU initiation was assessed terms BPD-1-related inpatient (IP) admissions, emergency room (ER) visits, outpatient (OP) visits at responding clinician’s practice. Results between cohorts using Chi-square Wilcoxon rank-sum tests. A total 107 taking 93 included analysis. Patients both groups similar average age (lurasidone: 37 years; cariprazine: 39 years), sex 48% male; 46% male), time since diagnosis 7 8 years). Average observed 14 months. significantly higher proportion experienced any IP admission to 1%; 9%; p<0.05). Proportions ER 3%; p=0.63) OP 68%; 81%; p=0.07) visit not statistically different groups. number (7.4) those (5.4; In this study, had low rates visits; hospitalization lower cariprazine.